Ghost Tree Capital’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $15M | Buy |
120,000
+65,000
| +118% | +$8.99M | 4.53% | 3 |
|
|
2024
Q2 | $8.69M | Sell |
55,000
-70,000
| -56% | -$8.99M | 2.72% | 13 |
|
|
2024
Q1 | $16.2M | Buy |
125,000
+25,000
| +25% | +$3.06M | 4.48% | 3 |
|
|
2023
Q4 | $9.64M | Buy |
100,000
+60,000
| +150% | +$5.76M | 3.15% | 7 |
|
|
2023
Q3 | $4.85M | Sell |
40,000
-45,000
| -53% | -$5.09M | 1.59% | 21 |
|
|
2023
Q2 | $9.73M | Buy |
85,000
+25,000
| +42% | +$3.22M | 3.21% | 11 |
|
|
2023
Q1 | $8.27M | Buy |
60,000
+5,000
| +9% | +$649K | 2.44% | 13 |
|
|
2022
Q4 | $7.13M | Sell |
55,000
-55,000
| -50% | -$6.37M | 3.04% | 15 |
|
|
2022
Q3 | $12.2M | Sell |
110,000
-20,000
| -15% | -$2.02M | 3.41% | 11 |
|
|
2022
Q2 | $9.74M | Buy |
130,000
+80,000
| +160% | +$5.89M | 5.08% | 5 |
|
|
2022
Q1 | $3.91M | Sell |
50,000
-50,000
| -50% | -$3.83M | 0.85% | 23 |
|
|
2021
Q4 | $9.01M | Buy |
+100,000
| New | +$8.55M | 3.23% | 12 |
|
|
2021
Q1 | – | Sell |
-40,000
| Closed | -$6.82M | – | 54 |
|
|
2020
Q4 | $6.82M | Sell |
40,000
-25,000
| -38% | -$3.7M | 1.52% | 24 |
|
|
2020
Q3 | $9.13M | Buy |
+65,000
| New | +$9.88M | 2.64% | 12 |
|
|
2020
Q1 | – | Sell |
-65,000
| Closed | -$8.39M | – | 61 |
|
|
2019
Q4 | $8.39M | Sell |
65,000
-155,000
| -70% | -$15.6M | 1.6% | 22 |
|
|
2019
Q3 | $16.6M | Sell |
220,000
-70,000
| -24% | -$8.27M | 4.22% | 5 |
|
|
2019
Q2 | $44.1M | Buy |
+290,000
| New | +$35.2M | 9.14% | 1 |
|
|
2019
Q1 | – | Sell |
-70,000
| Closed | -$7.64M | – | 43 |
|
|
2018
Q4 | $7.64M | Sell |
70,000
-140,000
| -67% | -$17.5M | 2.77% | 14 |
|
|
2018
Q3 | $33.9M | Buy |
210,000
+35,000
| +20% | +$4.78M | 7.21% | 2 |
|
|
2018
Q2 | $23.1M | Sell |
175,000
-60,000
| -26% | -$5.66M | 6.81% | 3 |
|
|
2018
Q1 | $17.4M | Buy |
+235,000
| New | +$15.7M | 3.52% | 5 |
|
|
2017
Q4 | – | Sell |
-100,000
| Closed | -$4.54M | – | 66 |
|
|
2017
Q3 | $4.54M | Buy |
+100,000
| New | +$4M | 0.96% | 37 |
|
|
2016
Q4 | – | Sell |
-150,000
| Closed | -$6.02M | – | 91 |
|
|
2016
Q3 | $9.21M | Sell |
150,000
-50,000
| -25% | -$1.51M | 1.49% | 24 |
|
|
2016
Q2 | $3.81M | Buy |
+200,000
| New | +$3.7M | 1.1% | 37 |
|
|
2016
Q1 | – | Sell |
-100,000
| Closed | -$3.86M | – | 64 |
|
|
2015
Q4 | $3.86M | Buy |
100,000
+90,000
| +900% | +$2.92M | 1.58% | 27 |
|
|
2015
Q3 | $321K | Buy |
+10,000
| New | +$339K | 0.14% | 71 |
|
Other funds holding SRPT
FCM
ACA
Ghost Tree Capital's SRPT Position: Q3 2024 in Review
Ghost Tree Capital increased its Sarepta Therapeutics (SRPT) stake by 118% in Q3 2024, buying an estimated $8.99M and bringing the position to 120,000 shares worth $15M. The position accounts for 4.53% of the portfolio, ranked #3.
Ghost Tree Capital first reported a position in SRPT in Q3 2015 and has held it in 26 quarters since. The position peaked at $44.1M in Q2 2019. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.
- Ghost Tree Capital held 120,000 shares of Sarepta Therapeutics worth $15M as of Q3 2024.
- Ghost Tree Capital bought 65,000 Sarepta Therapeutics shares in Q3 2024, an estimated $8.99M.
- Sarepta Therapeutics made up 4.53% of Ghost Tree Capital's portfolio in Q3 2024, its #3 holding.
- Ghost Tree Capital first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 26 quarters since.
- Ghost Tree Capital's Sarepta Therapeutics position peaked at $44.1M in Q2 2019.
- 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.
Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.